ABSTRACT
INTRODUCTION
Pre-eclampsia (PE) complicates 2-8% of all pregnancies and is a major cause of maternal morbidity 1 . Up to 18% of maternal deaths worldwide are secondary to PE complications, with an estimated 70 000 deaths per year 2 . Furthermore, it is directly responsible for one in seven preterm births 3 . Commonly, PE is a result of placental ischemia 4 due to defective trophoblastic invasion, which is followed by systemic clinical manifestations of the disease. Uterine artery (UtA) Doppler is a validated non-invasive proxy of this trophoblastic invasion 5 and placental perfusion 6 , which becomes abnormal at the preclinical stages of the disease. Indeed, in the second trimester, abnormal UtA Doppler is the best individual predictor of PE 7 . The only intervention that has been shown to reduce the risk of PE is low-dose aspirin, mainly in high-risk women 8 . However, the effect is only moderate (∼10% reduction) when given to the overall population 9 , highlighting the need to target those women with the highest risk. A meta-analysis of trials aimed at evaluating the impact of aspirin in women with abnormal second-trimester UtA Doppler failed to demonstrate any benefit of aspirin in reducing PE 10 , suggesting that advanced progression of the disease during the second trimester may have precluded effective prophylaxis. This has switched the focus of attention to the first trimester, when the disruption in trophoblastic invasion could already be detected by UtA Doppler 11 . However, the effect of aspirin in women with low or intermediate risk is not clear.
A small randomized study suggested that aspirin started before conception reduces uteroplacental vascular impedance during early and mid-gestation 12 . Furthermore, a retrospective study 13 showed that first-trimester initiation of aspirin significantly increased the magnitude of UtA improvement toward the third trimester. However, the effect of aspirin on trophoblastic invasion has not been evaluated prospectively within a first-trimester screening setting.
This study aimed to explore whether administration of low-dose aspirin from the first trimester improves trophoblastic invasion in women defined as high risk by abnormal UtA Doppler in the first trimester.
METHODS

Design and study population
This was a multicenter randomized parallel-arm, triple-blinded, Phase-II trial. From September 2012 to July 2015, all eligible women with singleton pregnancy attending routine ultrasound examination at 11-14 weeks of gestation at three university hospitals (Hospital Clinic, Barcelona University, Barcelona; Dexeus University Hospital, Barcelona; and Lozano Blesa University Hospital, Zaragoza) were interviewed for possible participation in a placebo-controlled, Phase-II randomized study. Inclusion criteria were as follows: (1) maternal age ≥ 18 years; (2) singleton pregnancy; (3) crown-rump length (CRL) of 45-84 mm; and (4) mean UtA pulsatility index (PI) > 95 th percentile 14 . Exclusion criteria were as follows: (1) pre-existing hypertensive, immune, renal or cardiovascular disease; (2) history of PE in previous pregnancy; (3) history of gastric ulcer; (4) known allergy or hypersensitivity to aspirin; (5) hemorrhagic disease; (6) fetal malformation (including chromosomopathy); or (7) active treatment with heparin or aspirin before recruitment.
The study was approved by the National Medicine Control Agency and the local ethics committee (EUDRACT no. 2012-000622-22). The study protocol was entered into the Clinical Trials Registry database (https:// clinicaltrials.gov/ct2/show/NCT01616615). The study design fulfilled Consolidated Standards of Reporting Trials (CONSORT) quality standard criteria for randomized trials. The study was carried out and monitored according to the guidance on good clinical practice issued by the European Medicines Agency (CPMP/ICH/135/95).
Randomization and monitoring
We used an online service (http://www.randomization .com) to generate randomized sequences in blocks of 10 subjects, stratified by participating center, to ensure balanced distributions within the study arms. The allocation sequence was sequestered by an independent Clinical Trials Unit. At enrollment, recruiting physicians faxed the Clinical Trials Unit for a 1 : 1 allocation ratio of 150 mg daily extended-release aspirin or identical-appearing placebo pills from the time of study inclusion (11-14 weeks) to 28 weeks. Medication or placebo was delivered to patients in identical blisters containing 30 pills at each research visit (15 + 0 to 17 + 6 weeks, 19 + 0 to 21+ 6 weeks, 23 + 0 to 25 + 6 weeks and 28 + 0 weeks ± 2 days) and compliance was assessed by pill counting after each period between visits. Low compliance was defined as more than 10% of pills returned on any visit during the follow-up. Women were advised to take the pill before bedtime.
Women who declined consent for study randomization but authorized the use of their baseline medical data were included in the database. These data were used for external validity testing of the trial. No candidate refused both randomization and collection of identifiable data. The study was triple-blinded with respect to subject, caregiver and investigator. Quality control of screening, data handling and verification of adherence to protocols at the different centers was performed on a regular basis by the trial coordinators.
Measurements and follow-up
Pregnancies were dated by the first-trimester CRL measurement 15 . The first visit occurred within 3 days after inclusion in the study, and the following characteristics were obtained: maternal age, height, ethnic origin (European, South American, North African or other), smoking during pregnancy (yes/no), parity (number of previous deliveries > 22 + 0 weeks), previous stillbirth (yes/no) and previous fetal growth restriction (FGR) (yes/no). Maternal weight was measured at each visit. Blood pressure (BP) was measured automatically at each visit with a calibrated Omron M6 Comfort (Omron Corp., Kyoto, Japan), twice in each arm with an appropriate cuff size, with the woman seated and after a 10-min rest. BP of the arm with the highest average mean arterial pressure was considered for analysis. UtA Doppler evaluation was performed at each visit by seven sonographers accredited by the Spanish Society of Ultrasound in Obstetrics, transvaginally at inclusion and transabdominally thereafter. For ultrasound examinations performed at 11-14 weeks, a transvaginal transducer was used to obtain a sagittal section of the cervix. The probe was moved laterally until the paracervical vascular plexus was seen. Color Doppler imaging was used to identify the UtA at the level of the cervicocorporeal junction. Measurements were taken at this point before the branching of the UtAs into the arcuate arteries. Pregnancies at 15-28 weeks were examined transabdominally. The probe was placed on the lower quadrant of the abdomen, angled medially, and color Doppler imaging was used to identify the UtA at the apparent crossover with the external iliac artery. Measurements were taken approximately 1 cm distal to the crossover point. In all cases, once it had been ensured that the angle was less than 30
• , the pulsed Doppler gate was placed over the whole width of the vessel. Angle correction was then applied and the signal updated until three similar consecutive waveforms had been obtained. The PI of the left and right arteries was measured and the mean PI was calculated. The mean UtA-PI was transformed to a Z-score according to published references 14 . Ultrasound biometry was assessed at 19-22 weeks and at 28 weeks. Abdominal circumference was measured and transformed to a Z-score according to local references 16 . The fetal weight at 28 weeks was estimated 17 from the following biometric parameters: biparietal diameter, head circumference, abdominal circumference and femur length. All measurements were obtained by one of seven trained sonographers who adhered to the recommended technique 16 .
Outcome measures
The main outcome variable was mean UtA-PI at 28 + 0 weeks ± 2 days. Secondary perinatal outcomes were: (1) development of PE (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg on two readings at least 4 h apart in previously normotensive women after 20 weeks of gestation, and proteinuria > 300 mg/24 h) 18 ; (2) early-onset PE, which required delivery before 34 weeks of gestation; (3) severe PE, defined as a BP ≥ 160/110 mmHg on two or more occasions, proteinuria ≥ 5 g/24 h, or the presence of maternal complications including: (i) eclampsia; (ii) hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome (lactate dehydrogenase > 600 IU/L, aspartate transaminase > 62 IU/L, platelet count < 100 × 10 9 /L); (iii) acute renal failure (creatinine > 1.2 mg/dL); (iv) subcapsular hepatic hematoma; (v) pulmonary edema (dyspnea, low oxygen saturation and compatible chest X-ray findings); (vi) placental abruption; or (vii) the presence of disseminated intravascular disease; (4) FGR and small-for-gestational age, defined as birth weight < 3 rd and < 10 th customized percentiles, respectively, according to local standards 19 ; (5) non-reassuring fetal status during labor, determined by a pathological fetal heart rate or a suspicious tracing 20 with fetal scalp blood pH < 7.15 or < 7.20 in two samples 30 min apart; (6) neonatal metabolic acidosis at birth, defined as umbilical arterial pH < 10 th percentile (pH 7.15) and base excess > 90 th percentile (12 mEq/L) 21 .
Sample size estimation and statistical analysis
Previous data 22 indicate that 30% of women with abnormal (pulsatile) UtA Doppler during the first trimester also have this abnormal condition in the third trimester. To reduce this rate of third-trimester abnormal UtA Doppler to 15% with the intervention (aspirin), we would have needed to include 120 experimental subjects and 120 control subjects to be able to reject the null hypothesis (uncorrected χ 2 ), so that the rates for experimental and control subjects are equal with a probability (power) of 80%. To compensate for a 10% rate of loss to follow-up, we aimed to recruit a total of 133 patients per arm. The probability of Type-I error associated with this test of the null hypothesis was set at 5%. The analyses were based on the originally assigned groups (intention-to-treat). Student's t-test (or non-parametric Mann-Whitney U-test) and Pearson's χ 2 (or Fisher's exact) tests were performed for univariate between-group comparisons of quantitative and qualitative variables, respectively. Open-source software (R; The R Foundation for Statistical Computing, Vienna, Austria) was used for all computations and graph construction.
RESULTS
During the study period, 8012 women were screened and 244 (3.1%) fulfilled the inclusion criteria and were invited to participate (Figure 1 ). Of these, 58 (23.8%) declined participation. Table S1 compares the baseline characteristics of the 186 women who agreed to participate with those of the 58 who declined participation: no characteristic was significantly different. Of the 186 randomized women, 94 were allocated to aspirin and 92 to placebo.
During the follow-up, 31 (16.7%) women were excluded for the following reasons: lost to follow-up (n = 13); voluntary withdrawal from the study (n = 11); major congenital malformation (n = 2, severe ventriculomegaly and large ventricular septal defect); preterm labor before the 28-week scan (n = 2, one preterm rupture of membranes and one spontaneous preterm labor); and miscarriage (n = 2, at 16 and 19 weeks). One additional woman had an adverse reaction (asthma attack) that required withdrawal from the study at 21 weeks (n = 1). The baseline characteristics of women who completed the study were compared with women who were excluded from it (Table S2) . Among women who were lost to follow-up, there was a significantly higher frequency of women of non-European ethnic origin, evenly distributed to placebo (n = 7) and aspirin (n = 6) groups. A total of 155 women completed the follow-up and were analyzed. Table 1 shows the clinical characteristics of these women according to study group. No woman had treatment compliance lower than 90%. During follow-up, 20 women (11 in the placebo group and nine in the aspirin group) presented with uterine bleeding. The bleeding did not require hospital admission or interruption of medication for any case. Table 2 shows the follow-up measurements according to study group. Noticeably, there was no difference in mean UtA-PI between women in the placebo and aspirin groups (Figure 2 ). Seven women developed PE: three (4%) in the placebo group and four (5%) in the aspirin group (Table 3 ). The gestational age at the onset of these cases ranged from 34 + 1 to 39 + 6 weeks. Two of the cases met the criteria for severe PE (one in each group): one with severe hypertension and one with incomplete HELLP syndrome. There was a trend towards a lower incidence of small-for-gestational age in the aspirin group (8.8% vs 17.3%; P = 0.11).
DISCUSSION
Our study failed to observe a significant effect of aspirin on trophoblastic flow resistance in women with evidence of defective invasion in the first trimester, as determined by abnormal UtA Doppler; however the study was underpowered to detect potential small effects. Few studies have evaluated the effect of low-dose aspirin on UtA flow. Our findings are not consistent with those of a previous small (n = 37), but methodologically sound, randomized study on women undergoing assisted reproductive techniques, in which aspirin was started before embryo transfer 12 . The previous study reported significantly lower arcuate artery resistance at 6 weeks of gestation and lower UtA resistance at 18 weeks of gestation. Several differences may account for these conflicting results. First, in the previous study, aspirin was started before conception. It is biologically plausible that earlier treatment with aspirin had a more pronounced effect on spiral artery remodeling. Indeed, early initiation of aspirin (before 16 weeks of gestation) has a more pronounced effect on reducing PE and FGR when compared with studies that initiated aspirin later in pregnancy 23 . Second, differences in patient characteristics may also explain the different results of the two studies. Infertile women may differ from the general population, with a higher proportion of women with defective uterine blood flow associated with immunohistochemical disruptions 24 . Consistent with this hypothesis, another randomized study of women undergoing in-vitro fertilization showed that aspirin improved the implantation rate and enhanced uterine blood flow 25 . An observational prospective study 26 of women at high risk for PE found that aspirin started at 11-14 weeks (n = 109) improved UtA Doppler compared with women without treatment (n = 296). Similarly, a retrospective analysis by Llurba et al. 13 of 183 women taking aspirin from the first trimester found that the decline in UtA-PI between the first and third trimesters was more pronounced than that in women without treatment. The design of these studies does not preclude women on aspirin from having different characteristics from those without treatment. Indeed, the latter study reported higher first-trimester UtA-PI values in women who received aspirin. Regression toward the mean phenomena could not be ruled out with such a study design.
Our finding of a lack of an aspirin effect in promoting trophoblastic invasion, as reflected by UtA Doppler, does not necessarily conflict with a benefit of aspirin in reducing the incidence of PE. Recent studies suggest that aspirin has a variety of actions in addition to the well-studied ability to inhibit cyclooxygenases 27 . Some of these effects may act via different pathways from those that enhance the trophoblast.
Our study did not contain sufficient power to assess the effect of aspirin in reducing the development of placenta-related diseases. However, we found a trend toward lower incidence of small-for-gestational age in women treated with aspirin. This is in agreement with the results of trials that started aspirin before 16 weeks 23 . Despite the lack of statistical significance, we believe that the publication of these results may attenuate the publication bias that was reported in a meta-analysis of these trials 23 , which suggested that small studies with negative effects were missing, primarily among trials in which aspirin was initiated before 16 weeks. A recent meta-analysis that excluded small studies failed to demonstrate any benefit of early low-dose aspirin administration in reducing PE 28 . Furthermore, the published trials on the effect of aspirin in women with abnormal UtA Doppler were performed on very high-risk populations, as suggested by an overall incidence of PE of approximately 30% 29 , which may affect the generalization of results showing a benefit.
UtA Doppler assessment during the second trimester has an excellent negative predictive value for early-onset PE 30 . Furthermore, sequential first-and second-trimester screening has good performance in ruling out the occurrence of PE 31 . Therefore, stopping aspirin treatment in high-risk women with normal UtA Doppler in the second trimester could be justified. However, it could be argued that because aspirin might have been responsible for the improvement, there is little rationale to stop treatment. Our results suggest that late normalization of UtA resistance cannot be attributed to aspirin, which leaves open the possibility of this contingent approach. This strategy requires further research.
We acknowledge several limitations of our study. First, participant recruitment was slow, which became more relevant over time. In many cases, women declined participation because they wanted to be guaranteed administration of aspirin rather than placebo. This maturation phenomenon also occurred in previous randomized trials of aspirin for the prevention of PE 32 . PE prevention with aspirin is currently recommended in many international guidelines [33] [34] [35] . Therefore, randomized trials on this issue are faced with increasing difficulty in meeting equipoise, and are more likely to have slow recruitment. In our study, despite the fact that enrolled women did not differ in their baseline characteristics from those who declined participation, we cannot rule out a selection bias because we were able to recruit only approximately 75% of the eligible women. This under-recruitment has an effect on the study power: the confidence interval of the mean difference between groups in the PI (Z-scores) at 28 weeks (-0.3 to 0.58) indicates that it is not powered to detect small reductions (< 0.30 SD) in UtA-PI. Furthermore, 17% of our study participants dropped out (primarily lost to follow-up or voluntary withdrawal from the study), which may have increased the risk of bias. Second, as discussed previously, our study was not intended to evaluate primarily the efficacy of aspirin in preventing PE. We excluded women with previous PE or pre-existing hypertensive, immune, renal or cardiovascular disease (we believed it would have been ethically questionable to allocate placebo to these participants) from the analysis. Therefore, our population had moderate risk and did not represent the whole spectrum of women who may have benefited from aspirin. The lower overall incidence of PE in our participants (approximately 5%) further suggests this could be the case. No quality assessment was undertaken on UtA Doppler measurement. However, all sonographers involved in this study were experienced. A final limitation of our study is that we do not have data on placental histology. These data could have given insights into the mechanisms by which aspirin may improve placental function.
In conclusion, our study shows that, for women with abnormal trophoblastic invasion (as reflected by abnormal UtA Doppler), low-dose aspirin started in the first trimester does not have a significant effect on UtA Doppler resistance as pregnancy progresses; however, the study was underpowered to detect potential small effects.
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